louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05946408: Effects of Antenatal Exercises in Primagravida
Official title: Effects Of Supervised Antenatal Exercises On Low Back Pain And Depression In Primigravida
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pregnancy Related
Keywords: Pregnancy Related
antenatal depression
low back pain
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-07-14
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this Randomized control trial is to determine the effects of antenatal exercises on low back pain in Primagravida. The main questions it aims to answer are whether supervised antenatal exercises have an effect on low back pain and depression in primagravida.

Detailed description: Females usually tend to avoid physical activity during pregnancy. Concept of antenatal exercises and its effects on low back pain or antenatal depression is yet not common amongst pregnant females in Pakistan. Low back pain and antenatal depression are common in pregnancy. These can have an impact on both their own health and the health of their unborn child. Understanding the benefits of antenatal exercises will encourage pregnant females to engage in regular physical activity. The results of this study will help physical therapists to implement effective exercise interventions for this population.

Eligibility criteria: Inclusion Criteria:

* Primagravida
* Single pregnancy
* Diagnosed for risk of Prenatal depression on EDPS \>10
* Pregnancy related Low back pain score of 3 to 8 on NPRS for at least 2 weeks.
* Females in 2nd Trimester of pregnancy

Exclusion Criteria:

* Any present or previous pelvic floor dysfunctions diagnosed by health professionals.
* Any physical disability causing inability to perform physical exercises.
* Any contraindications to physical activity according to ACOG
* Pelvic girdle pain (Anterior: Pubic symphysis, Posterior: SI joint Pain, Gluteal Pain, Piriformis syndrome).
* Rheumatoid disorders.
* Low back pain with radiation
* Not engaged in regular exercise.

Primary outcomes:
measure: Low back pain
timeFrame: 12th Week
measure: The Roland Morris Low Back Pain and Disability Questionnaire
timeFrame: 12th Week
measure: Beck depression inventory
timeFrame: 12th week
Secondary outcomes:
measure: Multidimensional Fatigue Inventory
timeFrame: 12th week
measure: Fear of Childbirth Questionnaire
timeFrame: 12th week
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Khyber Teaching Hospital
state: KPK
Study officials:
affiliation: Riphah International University
name: Sarah Ehsan, PP-DPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04212208: Pain Assessment in the Perioperative Area
Official title: Pain Assessment in the Perioperative Area During IV Cannulation Using a Combination of EMLA and Low-frequency USG Probe Versus a Combination of EMLA Cream and High-frequency Probe in Pediatric Cases- A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain, Procedural
Lead sponsor: All India Institute of Medical Sciences, Rishikesh
Sponsor class: OTHER_GOV
First posted: 2019-12-26
Enrollment: 120
Sex: ALL
Minimum age (years): 5
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is mainly focusing on reducing the pain scores during IV cannulation in pediatric population in the preoperative period. Applying EMLA cream is a well-known fact world wide. we would like to study the effect of ultrasound waves in the penetration of the given drung into the skin so that we could achieve the effect of the drug quickly.

Detailed description: To assess the intensity of pain in children in the perioperative area during IV cannulation using a combination of EMLA cream and low-frequency USG probe. To assess the intensity of pain in children in the perioperative area during IV cannulation using a combination of EMLA cream and high-frequency USG probe and final comparison between these groups will assess the effect of ultrasound in the penetration of the drug into the skin.

Eligibility criteria: Inclusion Criteria:

* All children in the preoperative period.

Exclusion Criteria:

Primary outcomes:
measure: To compare the intensity of pain among control versus interventional groups. Pain intensity assessment will be done using Faces Pain Scale-Revised (FPS-R)
timeFrame: 15minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Rishikesh
country: India
facility: AIIMS
state: Uttarakhand
Study officials:
affiliation: AIIMS Rishikesh
name: Vijay Adabala, MD
role: STUDY_CHAIR
References:
citation: Lucas VS, Burk RS, Creehan S, Grap MJ. Utility of high-frequency ultrasound: moving beyond the surface to detect changes in skin integrity. Plast Surg Nurs. 2014 Jan-Mar;34(1):34-8. doi: 10.1097/PSN.0000000000000031.
Clinical trial NCT01536808: Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?
Official title: Premature Aging and Type 2 Diabetes Mellitus: an Increased Risk of Cardiomyopathy?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes Mellitus
Keywords: Diabetes mellitus
accelerated aging
cellular senescence
diabetic cardiomyopathy
strain imaging
strain rate imaging,
echocardiography
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2012-02-22
Enrollment: 150
Sex: ALL
Minimum age (years): 40
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The potential clinical implications of this study are to optimise the selection of a population at risk for developing a diabetic cardiomyopathy among diabetic patients in order to develop early therapeutic strategies to prevent the left ventricular remodelling.

Therefore, the originality of this project is to hypothesize that :

* Diabetes mellitus is often associated with a premature aging syndrome
* Cellular senescence may potentiate the mechanisms that are involved in decreasing myocardial contractility in DM and,
* DM associated to premature aging may increase the risk of developing a cardiomyopathy Thus, the modulation of telomerase activity and the control of telomere length, together with the attenuation of the formation of reactive oxygen species, might represent important new targets in order to develop therapeutic tools in prevention of diabetic cardiomyopathy.


Eligibility criteria: Inclusion Criteria:

* Type 2 Diabetes mellitus
* 40 \< Age \< 55 years old
* oral antidiabetic or insulin treatment
* No symptoms
* Sinus rhythm
* no sign or history of heart disease
* LVEF \> 55%
* Absence of regional left ventricular motion abnormalities.

Exclusion Criteria:

* absence of sinus rhythm,
* silent ischemia defined as positive exercise test or positive stress echocardiography,
* history of cardiomyopathy or CAD,
* valvular heart disease hemodynamically significant,
* severe renal insufficiency defined as creatinine clearance \< 30 mL/min,
* echocardiographic images unsuitable for quantification,
* type 1 diabetes mellitus,
* Important diabetes mellitus imbalance defined as glycated hemoglobin \> 9% or glycemia \> 3g/L uncontrolled hypertension (\> 180/100 mmHg).

Primary outcomes:
measure: Telomere shortening
timeFrame: 36 months
Secondary outcomes:
measure: Dysfunction by speckle tracking imaging
timeFrame: 36 months
measure: Determine the predictive value of alteration
timeFrame: 36 months
measure: Cardiovascular events
timeFrame: 36 months
Other outcomes:
Locations:
city: Bron
country: France
facility: Laboratoire d'échocardiographie
Study officials:
affiliation: Hospices Civils de Lyon - Hôpital Louis Pradel
name: Geneviève Dérumeaux, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04571008: Effect of NMN Supplementation on Organ System Biology
Official title: Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Organ System Biology
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glucose Metabolism Disorders
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
First posted: 2020-09-30
Enrollment: 56
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.

Detailed description: This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.

Eligibility criteria: Inclusion Criteria:

* BMI 25.0-50.0 kg/m²
* Prediabetes defined as fasting plasma glucose of ≥100 mg/dL, or HbA1C ≥5.7, or HOMA-IR ≥2.5.

Exclusion Criteria:

* Women who are still having menses
* Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
* Persons who consume moderate-large amounts of caffeine daily (\>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
* Unstable weight (\>3% change during the last 2 months before entering the study)

Primary outcomes:
measure: Change in Muscle insulin sensitivity
timeFrame: before and after at least 16 weeks of treatment
Secondary outcomes:
measure: Changes in glucose tolerance
timeFrame: before and after at least 16 weeks of treatment
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Samuel Klein, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04279808: Adequate Insertion Depth of Dilator During Central Venous Catheterization
Official title: Adequate Insertion Depth of Dilator During Central Venous Catheterization Through the Right Internal Jugular Vein
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Central Venous Catheterization
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: SMG-SNU Boramae Medical Center
First posted: 2020-02-21
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trial
Primary purpose: PREVENTION

Brief summary: For safe central catheterization, clinicians must be aware of adequate dilator insertion depth not to directly dilate the venous wall. The purpose of the study is to find out adequate insertion depth of the dilator during central venous catheterization through the internal jugular vein with the aid of real-time ultrasonography.

Detailed description: This randomized controlled trial is to compare the distance between the skin puncture site and the outside of anterior wall of the internal jugular vein measured by real-time ultrasonography with the conventional method which is routinely used in common clinical practice.

Eligibility criteria: Inclusion Criteria:

* adult patients requiring central venous catheterization through the right internal jugular vein

Exclusion Criteria:

* suspicion for infection of the right neck site

Primary outcomes:
measure: hematoma realted with the dilator
timeFrame: 1 Day (on the study day for each patient)
Secondary outcomes:
measure: distance between skin puncture site and the outside of the anterior wall of the internal jugular vein
timeFrame: 1 Day (on the study day for each patient)
Other outcomes:
Locations:
Study officials:
affiliation: SMG-SNU Boramae Medical Center
name: Jung-Man Lee, M.D.,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02550223: Ultrasound Guided Radial Artery Catheterization
Official title: Ultrasound Guided Radial Artery Cathetrization, A Novel Technique.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arterial Catheterization, Peripheral
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2015-09-15
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Comparing an novel technique ( oblique view) during ultrasound guided radial artery catheterization versus Transverse and longitudinal views


Eligibility criteria: Inclusion Criteria:

* all patients with clear indication to radial artery catheterization like hemodynamic instability or the need of frequent arterial samples

Exclusion Criteria:

* refusal, Peripheral arterial diseases

Primary outcomes:
measure: success rate of radial artery cathertrization
timeFrame: postoperate 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura university
state: Dkahleya
Study officials:
References:
citation: Flumignan RL, Trevisani VF, Lopes RD, Baptista-Silva JC, Flumignan CD, Nakano LC. Ultrasound guidance for arterial (other than femoral) catheterisation in adults. Cochrane Database Syst Rev. 2021 Oct 12;10(10):CD013585. doi: 10.1002/14651858.CD013585.pub2.
Clinical trial NCT00791323: Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Inflammation
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2008-11-14
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy


Eligibility criteria: Inclusion Criteria:

* Patients scheduled to undergo phakic IOL implantation

Exclusion Criteria:

* History of intraocular surgery in the operative eye

Primary outcomes:
measure: Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels
timeFrame: Day 3
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
state: Texas
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT02117323: Corneal Opacities in Children
Official title: Observational Study on Corneal Opacities in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Corneal Opacities
Keywords: corneal opacities
Optical coherence tomography
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Eye Institute (NEI)
First posted: 2014-04-17
Enrollment: 54
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Infants and children (1 month to 18 years of age) with corneal opacity requiring a thorough eye examination.

Brief summary: A prospective observational study on corneal opacities in infants and children (1 month to 18 years old) will be conducted at CHLA. Most of these cases will be due to congenital corneal opacity (e.g. Peter's anomaly, mucopolysacharidoses) or scarring due to infectious keratitis. Sixty (60) subjects will be recruited. The children will be examined under anesthesia with a portable slit-lamp and OCT. An iVue OCT system (Optovue) attached to an operating microscope-style mount at CHLA will be used for the intraoperative scans. Both cross-sectional and 3-D OCT scans will be performed to assess opacity depth, pachymetry map, endothelial defects, and any abnormal adhesion between the cornea, iris and lens. The anterior chamber angle will also be imaged with cross-sectional OCT to assess angle depth, trabecular meshwork, Schwalbe's line, and possible peripheral iridocorneal adhesion or posterior embryotoxon. OCT of the crystalline lens will be obtained to assess the presence of cataract. Slit-lamp photography will be obtained, and gonioscopy will be performed if indicated. Corneal diameter will be measured with a caliper, and intraocular pressure will be measured with a tonopen (Reichert).


Eligibility criteria: Inclusion Criteria:

* Infants and children (1 month to 18 years of age) with corneal opacity requiring a thorough eye examination.

Exclusion Criteria:

* Inability to give informed consent.
* Inability to maintain stable fixation for OCT imaging.
* Inability to commit to required visits to complete the study.

Primary outcomes:
measure: Number of suitable subjects
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Children's Hospital Los Angeles
state: California
Study officials:
affiliation: Children's Hospital Los Angeles
name: Bibiana Reiser, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01213823: Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
Official title: Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Invasive Candidiasis
Candidemia
Keywords: invasive candidiasis
candidemia
severe hepatic injury
echinocandins
anidulafungin
caspofungin
micafungin
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-10-04
Enrollment: 536
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Acute-care inpatients aged 18 years or older, with at least one dose of echinocandin antifungal therapy during the hospitalization and a primary or secondary ICD-9 discharge diagnosis of invasive candidiasis / candidemia identified in the Premier's PerspectiveTM Comparative Database (PCD) from 01 June 2006 to 30 June 2008.

Brief summary: The purpose of this study is to estimate the relative risk of severe hepatic injury in hospitalized patients with invasive candidiasis and candidemia who received anidulafungin, compared to patients who received caspofungin and/or micafungin.


Eligibility criteria: Inclusion Criteria:

* Acute-care inpatients;
* Aged 18 years or older;
* At least one dose of echinocandin therapy during the hospitalization;
* Primary or secondary ICD-9 discharge diagnosis of invasive candidiasis / candidemia.

Exclusion Criteria:

* \< 18 years of age;
* No recorded echinocandin therapy during hospitalization;
* Acetaminophen hepatotoxicity;
* Pre-existing autoimmune hepatitis;
* Autoimmune/metabolic liver disease;
* Primary biliary cirrhosis;
* Primary sclerosing cholangitis and orthotopic liver transplantation.

Primary outcomes:
measure: Number of Any Severe Hepatic Injury Cases and Matched Controls
timeFrame: 01 June 2006 to 30 June 2008 (up to 25 Months)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00188123: Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With Magnetic Resonance Imaging (MRI)
Official title: Rapid Diagnosis of Myocardial Damage and Coronary Stenosis With MRI
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Infarction
Keywords: Myocardial infarction
MRI late enhancement
Atrial fibrillation
Lead sponsor: University Hospital, Linkoeping
Sponsor class: OTHER
Collaborators: name: Jonkoping County Hospital
name: Medical Research Council of Southeast Sweden
First posted: 2005-09-16
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with an in-hospital diagnosis of myocardial infarction having permanent atrial fibrillation.

Brief summary: The hypothesis is that single-shot imaging of myocardial infarction is possible in atrial fibrillation using MRI late enhancement technique

Detailed description: 50 outpatients in Jonkoping County with a diagnosis of in-hospital myocardial infarction, are asked to participate in this study comparing segmented true FISP late enhancement with single-shot trueFISP late enhancement for the diagnosis of myocardial damage. The study does not intervene regarding treatment but is a comparison of the diagnostic power of the two MRI techniques.

Eligibility criteria: Inclusion Criteria:

in-hospital diagnosis of myocardial infarction

Exclusion Criteria:

pacemaker, not willing to participate, metallic objects in brain or eyes,

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Varnamo
country: Sweden
facility: Varnamo Hospital
Study officials:
affiliation: University Hospital, Linkoeping
name: Jan E Engvall, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00838123: Cognitive Functioning Related to Job Tenure Among Patients With Schizophrenia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2009-02-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: schizophrenia

Brief summary: The aim of this research is to explore which cognitive function would affect the job tenure among people with schizophrenia. The investigators plan to recruit 60 people diagnosed with schizophrenia and divide into two groups, employment and unemployment. The investigators will use several cognitive function tests to collect their cognitive functions and PANSS to evaluate their psychotic symptoms. And then the investigators will compare and analysis the data through statistic software. Finally, the investigators will have the answer about if cognitive functions would affect the job tenure among people with schizophrenia. And the investigators hope that we could get the predict factor of cognitive function to predict the successful employment in future.


Eligibility criteria: Inclusion Criteria:

* schizophrenia, 18\~44y/o

Exclusion Criteria:

* substance abuse

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: